These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 11266416)

  • 1. In vitro pharmacodynamic modelling simulating free serum concentrations of fluoroquinolones against multidrug-resistant Streptococcus pneumoniae.
    Zhanel GG; Walters M; Laing N; Hoban DJ
    J Antimicrob Chemother; 2001 Apr; 47(4):435-40. PubMed ID: 11266416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
    Zhanel GG; Roberts D; Waltky A; Laing N; Nichol K; Smith H; Noreddin A; Bellyou T; Hoban DJ
    J Antimicrob Chemother; 2002 May; 49(5):807-12. PubMed ID: 12003975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
    Coyle EA; Kaatz GW; Rybak MJ
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1654-9. PubMed ID: 11353608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic activity of garenoxacin against ciprofloxacin-resistant Streptococcus pneumoniae.
    Zhanel GG; James J; Derkatch S; Laing N; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2006 Jul; 58(1):112-6. PubMed ID: 16644764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence of resistance.
    Thorburn CE; Edwards DI
    J Antimicrob Chemother; 2001 Jul; 48(1):15-22. PubMed ID: 11418508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences between two new quinolones (gemifloxacin and trovafloxacin) and ciprofloxacin in their concentration-dependent killing of Streptococcus pneumoniae.
    Joyanes P; Pascual A; Giménez MJ; García I; Aguilar L; Perea E
    Chemotherapy; 2001 Dec; 47(6):409-14. PubMed ID: 11786655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations.
    Zhanel GG; DeCorby M; Noreddin A; Mendoza C; Cumming A; Nichol K; Wierzbowski A; Hoban DJ
    J Antimicrob Chemother; 2003 Jul; 52(1):83-8. PubMed ID: 12775677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic activity of telithromycin at simulated clinically achievable free-drug concentrations in serum and epithelial lining fluid against efflux (mefE)-producing macrolide-resistant Streptococcus pneumoniae for which telithromycin MICs vary.
    Zhanel GG; Johanson C; Laing N; Hisanaga T; Wierzbowski A; Hoban DJ
    Antimicrob Agents Chemother; 2005 May; 49(5):1943-8. PubMed ID: 15855517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model.
    Lister PD; Sanders CC
    Antimicrob Agents Chemother; 1999 May; 43(5):1118-23. PubMed ID: 10223923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model.
    Firsov AA; Alferova IV; Smirnova MV; Lubenko IY; Portnoy YA; Zinner SH
    Int J Antimicrob Agents; 2005 May; 25(5):409-13. PubMed ID: 15848296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations.
    Zhanel GG; Johanson C; Hisanaga T; Mendoza C; Laing N; Noreddin A; Wierzbowski A; Hoban DJ
    J Antimicrob Chemother; 2004 Dec; 54(6):1072-7. PubMed ID: 15531596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers.
    Prieto J; Aguilar L; Fuentes F; Giménez MJ; Alou L; Dal-Ré R; Sörgel F; Frías J
    Int J Antimicrob Agents; 2001 Sep; 18(3):231-8. PubMed ID: 11673035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection.
    Lacy MK; Lu W; Xu X; Tessier PR; Nicolau DP; Quintiliani R; Nightingale CH
    Antimicrob Agents Chemother; 1999 Mar; 43(3):672-7. PubMed ID: 10049286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I; Cars O
    J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacodynamics of gatifloxacin and ciprofloxacin for pneumococci in an in vitro dynamic model: prediction of equiefficient doses.
    Zinner SH; Firsov AA; Gilbert D; Simmons K; Lubenko IY
    J Antimicrob Chemother; 2001 Dec; 48(6):821-6. PubMed ID: 11733466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of moxifloxacin against clinical isolates of Streptococcus pneumoniae from England and Wales.
    Johnson AP; Warner M; George RC; Livermore DM
    J Antimicrob Chemother; 2001 Apr; 47(4):411-5. PubMed ID: 11266412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model of infection.
    MacGowan AP; Rogers CA; Holt HA; Wootton M; Bowker KE
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2916-21. PubMed ID: 11557490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model.
    Ba BB; Feghali H; Arpin C; Saux MC; Quentin C
    Antimicrob Agents Chemother; 2004 Mar; 48(3):946-53. PubMed ID: 14982788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae.
    Lister PD; Sanders CC
    J Antimicrob Chemother; 1999 Jan; 43(1):79-86. PubMed ID: 10381104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model.
    Zelenitsky SA; Ariano RE; Iacovides H; Sun S; Harding GK
    J Antimicrob Chemother; 2003 Apr; 51(4):905-11. PubMed ID: 12654762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.